甲磺酸阿帕替尼治疗进展期胃癌的研究进展

doi:10.12092/j.issn.1009-2501.2019.10.017

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (10): 1194-1200.doi: 10.12092/j.issn.1009-2501.2019.10.017

• 综述与讲座 • 上一篇

甲磺酸阿帕替尼治疗进展期胃癌的研究进展

景钦东¹，刘海鹏²，王斌儒¹，陈康²，陈晓^2,3

¹兰州大学第二临床医学院，兰州 730030，甘肃；²兰州大学第二医院普通外科三病区，兰州 730030，甘肃；³甘肃省消化系肿瘤重点实验室，兰州 730030，甘肃

收稿日期:2019-05-14 修回日期:2019-10-04 出版日期:2019-10-26 发布日期:2019-10-28
通讯作者: 陈晓，男，硕士，主任医师，硕士研究生导师，研究方向：消化系统疾病。 Tel:13919055086 E-mail: chenxiaomd@163.com
作者简介:景钦东，男，在读硕士研究生，研究方向：消化道肿瘤。 Tel:13893173445 E-mail: 916435119@qq.com
基金资助:
北京市希思科临床肿瘤学研究基金（Y-HR2018-147）

Progress of apatinib in the treatment of advanced gastric cancer

JING Qindong¹, LIU Haipeng², WANG Binru ¹, CHEN Kang², CHEN Xiao ^2,3

¹ The Second Clinical Medical College of Lanzhou University, Lanzhou 730030, Gausu, China; ² Department Three of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu, China; ³Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030, Gansu, China

Received:2019-05-14 Revised:2019-10-04 Online:2019-10-26 Published:2019-10-28

摘要/Abstract

摘要：

胃癌是全球最常见的恶性肿瘤之一，其早期发现困难，发现时大多已失去手术机会。当前，全身综合治疗是进展期胃癌的主要治疗方法，但是，由铂类和氟尿嘧啶类联合为代表的标准化疗方案对于进展期胃癌的疗效欠佳。随着靶向药物的不断研究和发展，靶向药物在进展期胃癌治疗中占据了越来越重要的地位。甲磺酸阿帕替尼是我国自主研发并应用的一种小分子血管内皮生长因子(vascular endothelial growth factor,VEGF)受体抑制剂，高度选择性地竞争细胞内VEGF-2的三磷酸腺苷(adenosine triphosphate,ATP)结合位点，抑制肿瘤组织新生血管形成，进而抑制肿瘤组织的发生发展。本文系统地阐述了甲磺酸阿帕替尼治疗进展期胃癌的研究现状与进展，旨在为其进一步的临床应用提供参考依据。

关键词: 胃癌, 甲磺酸阿帕替尼, 血管内皮生长因子, 靶向治疗

Abstract:

Gastric cancer is one of the most common malignant tumors in the world. Early diagnosis is difficult and most patients have missed the best timing of surgery when diagnosed. Therefore, systemic comprehensive therapy should be the best treatment option for advanced gastric cancer. Recent years, the standard chemotherapy regimen, such as platinum and fluorouracil-based regimen has been proven poor efficacy. However, with continuous research and development, the role of targeted drugs has become increasingly important in the treatment of advanced gastric cancer. Apatinib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor developed and applied in China, which highly selectively competes with the binding site of adenosine triphosphate (ATP) of VEGF-2 in cells, inhibits the formation of new blood vessels in tumor tissues, and then inhibits the occurrence and development of tumor tissues. This article systematically reviewed the current research status and progress of apatinib in the treatment of advanced gastric cancer in order to provide a reference for further clinical application.

Key words: gastric cancer, apatinib, vascular endothelial growth factor, targeted therapy

中图分类号:

R453.9

景钦东，刘海鹏，王斌儒，陈康，陈晓. 甲磺酸阿帕替尼治疗进展期胃癌的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(10): 1194-1200.

JING Qindong, LIU Haipeng, WANG Binru, CHEN Kang, CHEN Xiao. Progress of apatinib in the treatment of advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1194-1200.

参考文献

［1］Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008［J］. Int j Cancer, 2013, 132(5):1133-1145.
［2］Liu Y, Zhang X, Chen L, et al. Cancer incidence and mortality in Gansu province, 2012［J］, Chin J Cancer Res，2016, 28(3):301-310.
［3］Shan F, Miao R, Xue K, et al. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials［J］. Cancer Lett, 2016, 380(2):598-607.
［4］Kerbel RS. Tumor angiogenesis［J］. N Engl J Med,358(19):2039-2049.
［5］Ferrara N, Gerber HP, LeCouter J, The biology of VEGF and its receptors［J］. Nat Med,2003,(9):669-676.
［6］Dvorak HF, Brown LF, Detmar M, Dvorak AM, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis［J］. Am J Pathol,1995,146(5):1029-1039.
［7］秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识［J］.临床肿瘤学杂志, 2015,20(9):841-847.
［8］National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology: Gastric cancer (Version 2. 2015)［EB /OL］. 2015［2015-08-10］. http:// www. nccn. org/professionals/physiciangls/pdf/gastric.pdf.
［9］Paul C, Luisa IA, Liguang L, et al. VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29［C］. Proc Amer Assoc Cancer Res,2006, 47:1746.
［10］陈淑慧,阳帆帆,何君,等.胃癌靶向治疗研究最新进展［J］.中国临床药理学与治疗学,2015,20(8):950-955.
［11］Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis［J］. J Clin Oncol, 2005,23(5):1011-1027.
［12］Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition［J］. Cell Signal, 2007,19(10):2003-2012.
［13］Tian S, Quan H, Xie C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo［J］.Cancer Science,2011,102(7):1374-1380.
［14］陈祖华,张朦琦,高静,等.阿帕替尼治疗小鼠人源化胃癌移植瘤模型的疗效观察及CD31的意义［J］.基础医学与临床,2018,38(12):1696-1701.
［15］Li J,Zhao X,Chen L,et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies［J］.BMC Cancer,2010,5(10):529.
［16］Li J, Qin S, Xu J, et al. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma［C］//全国临床肿瘤学大会暨年csco. 2011.
［17］Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol,2016, 34(13):1448-1454.
［18］胡刚,阿帕替尼治疗晚期胃癌疗效分析［J］.内蒙古医学杂志,2018,50(2):142-144.
［19］刘朝敏,王少龙,姜鹤群,等.阿帕替尼对二线化疗失败的晚期胃癌患者预后的影响［J］.成都医学院学报,2018,13(2):158-161,177.
［20］樊翠珍,张晓静,初玉平,等.阿帕替尼治疗化疗失败的进展期胃癌的疗效及安全性［J］.肿瘤,2018,38(4):356-361.
［21］郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析［J］.实用癌症杂志,2017,32(6):996-998.
［22］Zhang Y,Gou M,Han C,et al.Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer:a single-center observational study［J］.Anticancer Drugs,2017,5.DOI:10.1097/CAD.0000000000000582.
［23］黄毅超,刘云军,何宛谦,等.阿帕替尼与替吉奥联合治疗晚期胃癌疗效分析及对相关细胞因子的影响［J］.中国中西医结合消化杂志,2018,26(3):252-255.
［24］吴志伟,蔡俊,陆网坤,等.阿帕替尼联合替吉奥二线治疗晚期胃癌的临床观察［J］.中国当代医药,2017,24(23):69-75.
［25］杨欣怡,李宁,邓文英,等.阿帕替尼联合替吉奥与阿帕替尼二线治疗晚期胃癌的临床疗效比较［J］.肿瘤基础与临床,2017,30(6):483-486.
［26］Wang Y, Bi M, Zhang H, et al. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease［J］. Asia Pac J Clin Oncol,2017,13(5):e528-e530.
［27］Yang Y, Zhang W, Yao J, et al. First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy［J］. Cancer Biol Ther, 2018,19(5):355-358.
［28］樊鑫鑫,吕慧芳,陈贝贝,等.替吉奥联合阿帕替尼一线治疗晚期胃癌的临床效果观察并文献复习［J］.中国医学前沿杂志,2017,9(2):63-67.
［29］Zhang H.Apatinib for molecular targeted therapy in tumor［J］.Drug Des Devel Ther,2015,13(9):6075-6081.
［30］段洪瑞,宋岩,姜晓艳.阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌的疗效观察［J］.中国实用医药,2017,12(28):155-157.
［31］田春艳,尹进波,许丰铭,等.阿帕替尼联合免疫调节剂治疗晚期胃癌的效果观察［J］.浙江医学,2018,40(9):996-997.
［32］赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价［J］.中外医疗,2017,36(35):127-129.
［33］宋朝阳.肿节风注射液联合阿帕替尼治疗晚期胃癌的临床研究［J］.现代药物与临床,2017,32(6):1114-1117.
［34］Zhang Y, Han C, Li J, et al. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study［J］. Sci Rep, 2017, 7(1):13208.
［35］Lee HJ, Moon JY, Baek SW. Is treatment-emergent toxicity a biomarker of efficacy of Apatinib in gastric cancer［J］ ? J Clin Oncol, 2016, 34(31):3823.
［36］Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study［J］. J Hematol Oncol, 2017,10(1):153.
［37］Chen Z, Huang W, Tian T, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer［J］. J Hematol Oncol,2018,11(1):20.
［38］Zhang S. Problematic analysis and inadequate toxicity data in phase III apatinib trial in gastric cancer［J］.J Clin Oncol, 2016, 34(31):3821.
［39］Fornaro L, Vasile E, Falcone A. Apatinib in advanced gastric cancer: A doubtful step forward［J］. J Clin Oncol,2016,34(31):3822-3823.
［40］Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer［J］.J Cancer Res Clin Oncol,2017,143(2):361-368.

[1]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[2]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[3]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[4]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[5]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[6]	封壮壮, 宋瑞平, 豆鹏程, 陈心怡, 左娇娇, 舒劲. 基于mTOR/Beclin1/LC3信号轴探讨制萎扶胃丸对胃癌前病变大鼠胃窦组织自噬的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 361-370.
[7]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[8]	王琳, 李重阳, 李帅虎, 高盛涵, 徐甜, 李飞. 肺癌中致病融合基因的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 877-885.
[9]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[10]	陈文捷, 王亚兵, 陈晓琳, 任俊玲, 赵晚君, 陈斌. 碘难治性分化型甲状腺癌的最新研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 116-120.
[11]	刘宸, 方梦蝶, 徐昊, 李超, 任娟, 左博文, 张衍梅. 苍术苷靶向癌蛋白BORIS抑制癌细胞增殖的作用区域[J]. 中国临床药理学与治疗学, 2021, 26(9): 1005-1013.
[12]	卢锐斌, 赵辉, 谢秋玲, 胡露, 郭朝万, 裴运林, 熊盛. 抗FGF-2纳米抗体抑制碱烧伤诱导大鼠角膜血管新生[J]. 中国临床药理学与治疗学, 2021, 26(6): 609-615.
[13]	江玉华, 支慧, 卢林明, 田大皓, 王晓庆, 葛钰, 谢尚富, 王琪. 皖南蝮蛇毒抑瘤组分-I逆转原代胃癌相关成纤维细胞促癌作用[J]. 中国临床药理学与治疗学, 2021, 26(4): 389-394.
[14]	帕孜来提·亚森, 袁浩, 路红, 郑亚, 王玉平, 周永宁. 胃癌靶向治疗药物临床实验研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 454-461.
[15]	谢荣容, 陈帜, 杨昱, 谢饶英, 李平平, 孙霜霜, 陈文俊. 肺鳞癌成纤维细胞生长因子受体分子改变及其治疗对策[J]. 中国临床药理学与治疗学, 2021, 26(2): 196-203.

甲磺酸阿帕替尼治疗进展期胃癌的研究进展

Progress of apatinib in the treatment of advanced gastric cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价